Correlation of immunological profile with phenotype and disease outcome in pemphigus

Acta Dermato-Venereologica

Volumn 90, Issue 4, 2010, Pages 401-405

  Herrero Gonzälez, Josep E ^a,b   Iranzo, Pilar ^b   Benítez, Daniel ^b   Lozano, Francisco ^b   Herrero, Carmen ^b   Mascaró Jr , José M ^b  

^a HOSPITAL DEL MAR   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

Author keywords

Autoantibodies; Desmoglein; ELISA; Immunofluorescence; Prognosis

Indexed keywords

AUTOANTIBODY; DESMOGLEIN 3 ANTIBODY; BIOLOGICAL MARKER; DESMOGLEIN 1; DESMOGLEIN 3; DSG1 PROTEIN, HUMAN; DSG3 PROTEIN, HUMAN;

ADULT; AGED; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; IMMUNOFLUORESCENCE; MALE; OUTCOME ASSESSMENT; PEMPHIGUS FOLIACEUS; PEMPHIGUS VULGARIS; PHENOTYPE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; BLOOD; COMPARATIVE STUDY; FLUORESCENT ANTIBODY TECHNIQUE; IMMUNOLOGY; IMMUNOPHENOTYPING; MIDDLE AGED; MORTALITY; PEMPHIGUS; PREDICTIVE VALUE; SEVERITY OF ILLNESS INDEX; SPAIN; TIME; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; AUTOANTIBODIES; BIOLOGICAL MARKERS; DESMOGLEIN 1; DESMOGLEIN 3; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HUMANS; IMMUNOPHENOTYPING; MALE; MIDDLE AGED; PEMPHIGUS; PHENOTYPE; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SPAIN; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77954892959     PISSN: 00015555     EISSN: None     Source Type: Journal    
DOI: 10.2340/00015555-0868     Document Type: Article

References (29)

1. Amagai M, Klaus-Kovtun V, Stanley JR. Autoantibodies against a novel epithelial cadherin in pemphigus vulgaris, a disease of cell adhesion. Cell 1991; 67: 869-877.
2. Schiltz JR, Michel B. Production of epidermal acantholysis in normal human skin in vitro by the IgG fraction from pemphigus serum. J Invest Dermatol 1976; 67: 254-260.
3. Anhalt GJ, Labib RS, Voorhees JJ, Beals TF, Diaz LA. Induction of pemphigus in neonatal mice by passive transfer of IgG from patients with the disease. N Engl J Med 1982; 306: 1189-1196.
4. Roscoe JT, Diaz L, Sampaio SA, Castro RM, Labib RS, Takahashi Y, et al. Brazilian pemphigus foliaceus autoantibodies are pathogenic to BALB/c mice by passive transfer. J Invest Dermatol 1985; 85: 538-541.
5. Rock B, Labib RS, Diaz LA. Monovalent Fab' immunoglobulin fragments from endemic pemphigus foliaceus autoantibodies reproduce the human disease in neonatal Balb/c mice. J Clin Invest 1990; 85: 296-299.
6. Amagai M, Hashimoto T, Shimizu N, Nishikawa T. Absorption of pathogenic autoantibodies by the extracellular domain of pemphigus vulgaris antigen (Dsg3) produced by baculovirus. J Clin Invest 1994; 94: 59-67.
7. Amagai M, Hashimoto T, Green KJ, Shimizu N, Nishikawa T. Antigen-specific immunoadsorption of pathogenic autoantibodies in pemphigus foliaceus. J Invest Dermatol 1995; 104: 895-901.
8. Amagai M, Tsunoda K, Suzuki H, Nishifuji K, Koyasu S, Nishikawa T. Use of autoantigen-knockout mice in developing an active autoimmune disease model for pemphigus. J Clin Invest 2000; 105: 625-631.
9. Mahoney MG, Wang Z, Rothenberger K, Koch PJ, Amagai M, Stanley JR. Explanations for the clinical and microscopic localization of lesions in pemphigus foliaceus and vulgaris. J Clin Invest 1999; 103: 461-468.
10. Ding X, Aoki V, Mascaro JM, Jr, Lopez-Swiderski A, Diaz LA, Fairley JA. Mucosal and mucocutaneous (generalized) pemphigus vulgaris show distinct autoantibody profiles. J Invest Dermatol 1997; 109: 592-596.
11. Amagai M, Tsunoda K, Zillikens D, Nagai T, Nishikawa T. The clinical phenotype of pemphigus is defined by the anti-desmoglein autoantibody profile. J Am Acad Dermatol 1999; 40: 167-170.
12. Acosta E, Gilkes JJ, Ivanyi L. Relationship between the serum autoantibody titers and the clinical activity of pemphigus vulgaris. Oral Surg Oral Med Oral Pathol 1985; 60: 611-614.
13. Judd KP, Lever WF. Correlation of antibodies in skin and serum with disease severity in pemphigus. Arch Dermatol 1979; 115: 428-432.
14. Creswell SN, Black MM, Bhogal B, Skeete MV. Correlation of circulating intercellular antibody titres in pemphigus with disease activity. Clin Exp Dermatol 1981; 6: 477-483.
15. Fitzpatrick RE, Newcomer VD. The correlation of disease activity and antibody titers in pemphigus. Arch Dermatol 1980; 116: 285-290.
16. Harman KE, Gratian MJ, Bhogal BS, Challacombe SJ, Black MM. The use of two substrates to improve the sensitivity of indirect immunofluorescence in the diagnosis of pemphigus. Br J Dermatol 2000; 142: 1135-1139.
17. Harman KE, Gratian MJ, Seed PT, Bhogal BS, Challacombe SJ, Black MM. Diagnosis of pemphigus by ELISA: a critical evaluation of two ELISAs for the detection of antibodies to the major pemphigus antigens, desmoglein 1 and 3. Clin Exp Dermatol 2000; 25: 236-240.
18. Ishii N, Maeyama Y, Karashima T, Nakama T, Kusuhara M, Yasumoto S, et al. A clinical study of patients with pemphigus vulgaris and pemphigus foliaceous: an 11-year retrospective study (1996-2006). Clin Exp Dermatol 2008; 33: 641-643.
19. Ljubojevic S, Lipozencic J, Brenner S, Budimcic D. Pemphigus vulgaris: a review of treatment over a 19-year period. J Eur Acad Dermatol Venereol 2002; 16: 599-603.
20. Bystryn JC, Steinman NM. The adjuvant therapy of pemphigus. An update. Arch Dermatol 1996; 132: 203-212.
21. Harman KE, Gratian MJ, Bhogal BS, Challacombe SJ, Black MM. A study of desmoglein 1 autoantibodies in pemphigus vulgaris: racial differences in frequency and the association with a more severe phenotype [see comments]. Br J Dermatol 2000; 143: 343-348.
22. Herrero-Gonzalez JE, Mascaro JM, Jr, Iranzo P, Herrero C. Atypical pemphigus: discordance between clinicopathological findings and the antigenic profile in four cases. J Cutan Pathol 2006; 33: 502-507.
23. Ng PP, Thng ST. Three cases of transition from pemphigus vulgaris to pemphigus foliaceus confirmed by desmoglein ELISA. Dermatology 2005; 210: 319-321.
24. Nagasaka A, Matsue H, Miyahara A, Shimada S. Pemphigus vulgaris with no mucosal lesions showing pemphigus-foliaceus-like skin manifestations: Is there a 'cutaneous type' of pemphigus vulgaris? Dermatology 2005; 211: 372-374.
25. Judd KP, Mescon H. Comparison of different epithelial substrates useful for indirect immunofluorescence testing of sera from patients with active pemphigus. J Invest Dermatol 1979; 72: 314-316.
26. O'Loughlin S, Goldman GC, Provost TT. Fate of pemphigus antibody following successful therapy. Preliminary evaluation of pemphigus antibody determinations to regulate therapy. Arch Dermatol 1978; 114: 1769-1772.
27. Cheng SW, Kobayashi M, Kinoshita-Kuroda K, Tanikawa A, Amagai M, Nishikawa T. Monitoring disease activity in pemphigus with enzyme-linked immunosorbent assay using recombinant desmogleins 1 and 3. Br J Dermatol 2002; 147: 261-265.
28. Harman KE, Seed PT, Gratian MJ, Bhogal BS, Challacombe SJ, Black MM. The severity of cutaneous and oral pemphigus is related to desmoglein 1 and 3 antibody levels. Br J Dermatol 2001; 144: 775-780.
29. Eming R, Rech J, Barth S, Kalden JR, Schuler G, Harrer T, et al. Prolonged clinical remission of patients with severe pemphigus upon rapid removal of desmoglein-reactive autoantibodies by immunoadsorption. Dermatology 2006; 212: 177-187.